Actively Recruiting

Phase 1
Age: 0 - 39Years
All Genders
NCT04972942

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Led by New York Medical College · Updated on 2026-04-15

30

Participants Needed

16

Research Sites

275 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.

CONDITIONS

Official Title

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Who Can Participate

Age: 0 - 39Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 0 to 39 years
  • Diagnosis of T-cell acute lymphoblastic leukemia in second or later remission with 5% or fewer blasts or relapsed T-cell lymphoblastic lymphoma with complete response after re-induction therapy
  • Planned allogeneic stem cell transplantation with donor identified
  • Performance status of 60% or higher
  • Fully recovered from acute toxic effects of prior chemotherapy, immunotherapy, or radiotherapy
  • Meet required organ function criteria
  • Signed informed consent approved by IRB
Not Eligible

You will not qualify if you...

  • Prior autologous or allogeneic stem cell transplant
  • Uncontrolled systemic infection at enrollment
  • Known allergy, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies, human proteins, or their components
  • Pregnant or actively breastfeeding
  • Positive for HIV, hepatitis B, or hepatitis C
  • Chronic obstructive pulmonary disease (COPD)
  • Asthma
  • Clinically significant heart disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Phoenix Children's Hospital

Phoeniz, Arizona, United States, 85016

Not Yet Recruiting

2

Loma Linda University Children's Hospital

Loma Linda, California, United States, 92354

Actively Recruiting

3

University of California

Los Angeles, California, United States, 90095

Not Yet Recruiting

4

University of California

San Francisco, California, United States, 94143

Actively Recruiting

5

Children's Hospital Colordao

Aurora, Colorado, United States, 80045

Not Yet Recruiting

6

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

Not Yet Recruiting

7

University of Florida

Gainsville, Florida, United States, 32608

Actively Recruiting

8

John Hopkins All Children's Hospital

St. Petersburg, Florida, United States, 33701

Not Yet Recruiting

9

Riley Children's Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

10

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

11

Helen DeVos Children's Hospital

Grand Rapids, Michigan, United States, 49503

Actively Recruiting

12

New York Medical College

Vallhala, New York, United States, 10595

Actively Recruiting

13

Nationwide Children's Hosptial

Columbus, Ohio, United States, 43205

Not Yet Recruiting

14

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

15

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Not Yet Recruiting

16

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Not Yet Recruiting

Loading map...

Research Team

L

Lauren Harrison, RN, MSN

CONTACT

E

Erin Morris, RN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | DecenTrialz